Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term lurasidone treatment in bipolar I disorder
2013-003039-31Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lurasidone in bipolar I disorder, sponsored by Sumitomo Pharma. Primary endpoint: Safety endpoints. Started May 2015; status: completed.
02
Drugs
lurasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2013-003039-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003039-31.